Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia

F. Lorentino, M. Labopin, F. Ciceri, L. Vago, K. Fleischhauer, B. Afanasyev, N. Kröger, JJ. Cornelissen, M. Lovira, E. Meijer, A. Vitek, A. Elmaagacli, D. Blaise, A. Ruggeri, C. Chabannon, A. Nagler, M. Mohty, Acute Leukemia Working Party (ALWP)...

. 2021 ; 35 (2) : 585-594. [pub] 20200514

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011541

HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation cyclophosphamide (PTCy) could modulate its negative impact on outcomes. We retrospectively compared acute leukemia patients receiving 10/10 or 9/10 HLA allele-matched UD-HCT with PTCy-GvHD prophylaxis between 2010 and 2017, reported to EBMT registry. The 100-day incidence of grade ≥2 and grade ≥3 aGvHD were comparable for 10/10 and 9/10 UD (28% versus 28%, p = 0.8 and 10% versus 8%, p = 0.5, respectively). The 2-year cGvHD and extensive cGvHD were similar between 10/10 and 9/10 UD (35% versus 44%, p = 0.2 and 21% versus 20%, p = 0.6, respectively). The 2-year nonrelapse mortality was 20% after 10/10 and 16% after 9/10 UD-HCT (p = 0.1). Relapse incidence at 2-year was 24% for 10/10 and 28% for 9/10 UD-HCT (p = 0.4). Leukemia-free survival at 2-year was the same for 10/10 and 9/10 UD (56 and 56%, p = 0.6, respectively), with comparable overall survival (62 and 59%, p = 0.9, respectively). Multivariate analysis showed no effect of HLA-matching on outcomes. An advanced disease status and patient disability remained the most important factors portending a worse survival. PTCy could alleviate the detrimental effect of HLA-allele mismatching in UD-HCT, potentially expanding the donor pool for acute leukemia patients.

Acute Leukemia Working Party of EBMT Paris France

Asklepios Klinik St George Lohmühlenstrasse Hamburg Germany

Cellular Therapy and Immunobiology Working Party Marseille France

Centre d'Investigations Cliniques en Biothérapies Institut Paoli Calmette Marseille Marseille France

Department of Hematology University Medical Center Amsterdam Netherlands

Department of Pediatric Hematology and Oncology IRCCS Bambino Gesù Children's Hospital Rome Italy

Department of Stem cell Transplantation University Hospital Eppendorf Hamburg Germany

Erasmus MC Daniel den Hoed Cancer Centre Rotterdam Netherlands

German Cancer Consortium Heidelberg Germany

Hematology and Bone Marrow Transplantation Unit IRCCS San Raffaele Scientific Institute Milano Italy

Hôpital Saint Antoine Paris University UPMC INSERM U938 Paris France

Hospital Clinic Institute of Hematology and Oncology Barcelona Spain

Institute for Experimental Cellular Therapy Essen University Hospital Essen Germany

Institute of Hematology and Blood Transfusion Prague Czech Republic

Programme de Transplantation and Thérapie Cellulaire Centre de Recherche en Cancérologie de Marseille Institut Paoli Calmettes Marseille France

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology Hematology and Transplantation St Petersburg Russia

Service d'Hématologie Clinique et Thérapie Cellulaire Hôpital Saint Antoine AP HP Paris France

Unit of Immunogenetics Leukemia Genomics and Immunobiology IRCCS San Raffaele Scientific Institute Milano Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011541
003      
CZ-PrNML
005      
20240528153116.0
007      
ta
008      
210420s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-020-0863-4 $2 doi
035    __
$a (PubMed)32409688
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Lorentino, Francesca $u Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy. lorentino.francesca@hsr.it
245    10
$a Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia / $c F. Lorentino, M. Labopin, F. Ciceri, L. Vago, K. Fleischhauer, B. Afanasyev, N. Kröger, JJ. Cornelissen, M. Lovira, E. Meijer, A. Vitek, A. Elmaagacli, D. Blaise, A. Ruggeri, C. Chabannon, A. Nagler, M. Mohty, Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)
520    9_
$a HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation cyclophosphamide (PTCy) could modulate its negative impact on outcomes. We retrospectively compared acute leukemia patients receiving 10/10 or 9/10 HLA allele-matched UD-HCT with PTCy-GvHD prophylaxis between 2010 and 2017, reported to EBMT registry. The 100-day incidence of grade ≥2 and grade ≥3 aGvHD were comparable for 10/10 and 9/10 UD (28% versus 28%, p = 0.8 and 10% versus 8%, p = 0.5, respectively). The 2-year cGvHD and extensive cGvHD were similar between 10/10 and 9/10 UD (35% versus 44%, p = 0.2 and 21% versus 20%, p = 0.6, respectively). The 2-year nonrelapse mortality was 20% after 10/10 and 16% after 9/10 UD-HCT (p = 0.1). Relapse incidence at 2-year was 24% for 10/10 and 28% for 9/10 UD-HCT (p = 0.4). Leukemia-free survival at 2-year was the same for 10/10 and 9/10 UD (56 and 56%, p = 0.6, respectively), with comparable overall survival (62 and 59%, p = 0.9, respectively). Multivariate analysis showed no effect of HLA-matching on outcomes. An advanced disease status and patient disability remained the most important factors portending a worse survival. PTCy could alleviate the detrimental effect of HLA-allele mismatching in UD-HCT, potentially expanding the donor pool for acute leukemia patients.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a nemoc štěpu proti hostiteli $x farmakoterapie $x etiologie $x mortalita $x patologie $7 D006086
650    _2
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a testování histokompatibility $7 D006650
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a akutní myeloidní leukemie $x mortalita $x patologie $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x mortalita $x patologie $x terapie $7 D009364
650    _2
$a akutní lymfatická leukemie $x mortalita $x patologie $x terapie $7 D054198
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a příprava pacienta k transplantaci $7 D019172
650    _2
$a homologní transplantace $7 D014184
650    12
$a nepříbuzný dárce $7 D061349
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u Hôpital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France ; Acute Leukemia Working Party of EBMT, Paris, France ; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France
700    1_
$a Ciceri, Fabio $u Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
700    1_
$a Vago, Luca $u Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy $u Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy
700    1_
$a Fleischhauer, Katharina $u Institute for Experimental Cellular Therapy, Essen University Hospital, Essen, Germany ; German Cancer Consortium, Heidelberg, Germany
700    1_
$a Afanasyev, Boris $u Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, St. Petersburg, Russia
700    1_
$a Kröger, Nicolaus $u Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Cornelissen, Jan J $u Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands
700    1_
$a Lovira, Montserrat $u Hospital Clinic Institute of Hematology & Oncology, Barcelona, Spain
700    1_
$a Meijer, Ellen $u Department of Hematology, University Medical Center, Amsterdam, Netherlands
700    1_
$a Vitek, Antonin $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Elmaagacli, Ahmet $u Asklepios Klinik St. George, Lohmühlenstrasse, Hamburg, Germany
700    1_
$a Blaise, Didier $u Programme de Transplantation & Thérapie Cellulaire - Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
700    1_
$a Ruggeri, Annalisa $u Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy ; Cellular Therapy and Immunobiology Working Party (CTIWP), Marseille, France
700    1_
$a Chabannon, Christian $u Cellular Therapy and Immunobiology Working Party (CTIWP), Marseille, France ; Centre d'Investigations Cliniques en Biothérapies, Institut Paoli Calmette Marseille, Marseille, France
700    1_
$a Nagler, Arnon $u Hôpital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France ; Acute Leukemia Working Party of EBMT, Paris, France
700    1_
$a Mohty, Mohamad $u Hôpital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France ; Acute Leukemia Working Party of EBMT, Paris, France ; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France $7 xx0317729
710    2_
$a Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 35, č. 2 (2021), s. 585-594
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32409688 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20240528153112 $b ABA008
999    __
$a ok $b bmc $g 1650043 $s 1131920
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 2 $d 585-594 $e 20200514 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace